Centrical Raises $39.0

Marble

Marble is building intelligent, turnkey automation solutions to revolutionize food supply chains, beginning in the meat industry. By integrating food-grade hardware with AI, next-gen software, computer vision, robotics, data analytics, and advanced process engineering, Marble is developing an intelligent technology platform to power the processing facility of the future. Our solutions automate entire processes, enabling processors to reduce labor, optimize yields, and operate more efficiently. All the hardware and software are developed and supported by Marble. If you'd like to learn more or see our technology in action at our innovation center in Lincoln, NE, please email us at hi@seemarble.com or call us at 617-453-8356.

Aippy

Aippy is the community designed to foster a vibrant space where creators can effortlessly build, share, and explore interactive projects using natural language. Founded with a vision to boost inspiring and interactive experiences beyond traditional coding, Aippy makes the entire creation process smoother and more seamless by launching its iOS app, which enables users to speak to generate prompts.

Quantinuum

Science led and enterprise driven, Quantinuum unites Cambridge Quantum’s best-in-class software with Honeywell Quantum Solutions’ high-performing trapped-ion hardware. We are scaling quantum computing and developing applications today to solve the world’s most pressing challenges.

Flourish

The Flourish platform helps RIAs (Registered Investment Advisors) grow by evolving from holistic advice to holistic implementation. The Flourish platform supports more than $8 billion in assets under custody and is used by more than 1100 wealth management firms representing more than $2.6 trillion in assets under management. Flourish is wholly-owned by MassMutual. For more information, visit www.flourish.com.

Goldenrod Therapeutics

Goldenrod Therapeutics is developing a new class of medicine targeting serious neurological conditions — including Friedreich's ataxia, other neurodegenerative diseases, substance use disorders, and immunological diseases. Our approach builds on a well-established biological pathway in the brain, improving on earlier treatments that were held back by side effects and tolerability issues. By achieving meaningful drug exposure in the brain while maintaining a favorable safety profile, we believe we can open the door to treatments that simply weren't possible before — reaching millions of patients with few or no good options today.